From LSD To GD To PD
This article was originally published in Start Up
You may also be interested in...
Investors and dealmakers are using recent discoveries about convergences between Gaucher’s disease and Parkinson’s in the lysosome to generate new therapeutic programs. Start-up Lysosomal Therapeutics thinks that the rare disorder can serve as a model system for developing new drugs to increase lysosomal function as a way to treat Parkinson’s disease and possibly other neurodegenerative disorders.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.